Ray Trapp: Build resilience to meet life's challenges
13 months from the diagnosis of stage three renal cell carcinoma and I sit here in awe of the audacity of resilience. (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - August 11, 2023 Category: Pharmaceuticals Authors: Ray Trapp Source Type: news
Ductal Carcinoma in Situ (DCIS): What It Is, Causes, Symptoms & Treatment
A breast cancer diagnosis can be terrifying, but one type of early-stage disease is noninvasive and has high survival odds.
There have been an estimated 297,790 new cases of breast cancer diagnosed in the United States so far this year, the U.S.... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - August 8, 2023 Category: General Medicine Source Type: news
S2 Episode 5: The Epidemiology of Renal Cell Carcinoma S2 Episode 5: The Epidemiology of Renal Cell Carcinoma
Drs Sumanta Pal and Laura Bukavina discuss the epidemiology of renal cell carcinoma, including risk factors, genetic screening, cystic disease, the microbiome, and the mycobiome.Medscape (Source: Medscape Pathology Headlines)
Source: Medscape Pathology Headlines - August 3, 2023 Category: Pathology Tags: Hematology-Oncology InDiscussion Source Type: news
MIT researcher discusses potential for wearable ultrasound patch
Canan DaĞdeviren, PhD, spoke with AuntMinnie.com about a wearabl...Read more on AuntMinnie.comRelated Reading:
Wearable ultrasound patch detects suspicious breast findings
Which women should receive ultrasound for breast screening?
CAD improves radiologists' breast ultrasound reading performance
AI shows perfect performance in invasive lobular carcinoma
AI performs well with portable breast ultrasound images (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - August 1, 2023 Category: Radiology Source Type: news
Adjuvant Everolimus Falls Short in High-Risk Kidney Cancer
(MedPage Today) -- Adjuvant everolimus (Afinitor) failed to significantly improve recurrence-free survival (RFS) in patients with renal cell carcinoma (RCC) who were at high risk for recurrence after nephrectomy, according to results from a randomized... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - July 31, 2023 Category: Hematology Source Type: news
Adjuvant Everolimus Falls Short in High-Risk Renal Cancer
(MedPage Today) -- Adjuvant everolimus (Afinitor) failed to significantly improve recurrence-free survival (RFS) in patients with renal cell carcinoma (RCC) who were at high risk for recurrence after nephrectomy, according to results from a randomized... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - July 31, 2023 Category: Hematology Source Type: news
Elderly Man Develops Facial Plaque After Salivary Duct Carcinoma Diagnosis
(MedPage Today) -- Clinicians consider a number of differential diagnoses before making the call (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - July 31, 2023 Category: Hematology Source Type: news
Wearable ultrasound patch detects suspicious breast findings
A wearable ultrasound patch showed success in a pilot study for detecting potentia...Read more on AuntMinnie.comRelated Reading:
AI doesn't improve breast cancer screening in dense breasts
Which women should receive ultrasound for breast screening?
AI model helps improve breast ultrasound interpretation
CAD improves radiologists' breast ultrasound reading performance
AI shows perfect performance in invasive lobular carcinoma (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - July 28, 2023 Category: Radiology Source Type: news
[Ad hoc announcement pursuant to Art. 53 LR] Roche reports strong growth in both divisions ’ base business; Group sales and profit reflect declining demand for COVID-19 products
Excluding COVID-19 products,Groupsales increase strongly by 8%1at constant exchange rates (CER)In line with the expected declining demand for COVID-19 products,Groupsales decrease 2% (-8% in Swiss francs)Pharmaceuticals Division sales grow strongly by 8% due to continued high demand for newer medicines; new eye medicine Vabysmo is the strongest growth driverDiagnostics Division ’s base businesscontinues its good growth momentum with an increase of 6%, while total divisional sales are 23% lower due to exceptionally high demand for COVID-19 tests in the first half of 2022Core earnings per share decrease 5%, driven by lower...
Source: Roche Investor Update - July 27, 2023 Category: Pharmaceuticals Source Type: news
[Ad hoc announcement pursuant to Art. 53 LR] Roche reports strong growth in both divisions ’ base business; Group sales and profit reflect declining demand for COVID-19 products
Basel, 27 July 2023Excluding COVID-19 products,Groupsales increase strongly by 8%1at constant exchange rates (CER)In line with the expected declining demand for COVID-19 products,Groupsales decrease 2% (-8% in Swiss francs)Pharmaceuticals Division sales grow strongly by 8% due to continued high demand for newer medicines; new eye medicine Vabysmo is the strongest growth driverDiagnostics Division ’s base businesscontinues its good growth momentum with an increase of 6%, while total divisional sales are 23% lower due to exceptionally high demand for COVID-19 tests in the first half of 2022Core earnings per share decrease ...
Source: Roche Media News - July 27, 2023 Category: Pharmaceuticals Source Type: news
Liquid Biopsy Shows Big Promise in Oropharyngeal Cancer Liquid Biopsy Shows Big Promise in Oropharyngeal Cancer
The blood test could aid diagnosis and surveillance of HPV-associated oropharyngeal squamous cell carcinoma, new research shows.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - July 17, 2023 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
Elevar Therapeutics Announces FDA Acceptance for Filing of New Drug Application for Rivoceranib in Combination with Camrelizumab as a First-line Treatment for Unresectable Hepatocellular Carcinoma
FORT LEE, NEW JERSEY, July 17, 2023– Elevar Therapeutics, Inc., a majority-owned subsidiary of HLB Co., Ltd. And a fully integrated biopharmaceutical company dedicated to elevating treatment experiences and outcomes for patients who have... (Source: Drugs.com - New Drug Applications)
Source: Drugs.com - New Drug Applications - July 17, 2023 Category: Drugs & Pharmacology Source Type: news
Adjuvant Nivolumab Promising in Resected Merkel Cell Carcinoma
(MedPage Today) -- Credit: Klaus D. Peter, Wiehl, Germany
Adjuvant therapy with nivolumab (Opdivo) was feasible and safe and appeared to prolong disease-free survival (DFS) in patients with completely resected Merkel cell carcinoma (MCC)... (Source: MedPage Today Dermatology)
Source: MedPage Today Dermatology - July 14, 2023 Category: Dermatology Source Type: news
AI plus CT improves cirrhosis prediction in liver disease patients
Adding artificial intelligence (AI) to CT imaging improves the prediction o...Read more on AuntMinnie.comRelated Reading:
AI and CT facilitate opportunistic screening for enlarged spleen
Photon-counting CT just as good as MRI for quantifying liver fat
Multiparametric MRI features can predict liver cancer recurrence
AI can identify hepatocellular carcinoma on liver CT exams
CT, ultrasound provide chance for fatty liver disease screening (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - July 13, 2023 Category: Radiology Source Type: news
Aggressive Pituitary Tumors and Pituitary Carcinomas Aggressive Pituitary Tumors and Pituitary Carcinomas
A better understanding of the pathology and clinical course of these rare and challenging tumors could help guide treatment decisions.Journal of Clinical Endocrinology & Metabolism (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - July 13, 2023 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news
